Many MDS and AML subtypes share common driver alterations which might occur at different frequencies but target the same pathways; for example DNA methylation (TET2, DNMT3A, and IDH1/IDH2), chromatin/histone modification (MLL2, EZH2 and ASXL1), RNA splicing (SF3B1, SRSF2, U2AF1, U2AF2, and SF3A1) or have mutations in TP53 gene, in RAS gene or in other signaling pathways [13, 14]. This evidence concerns the gene TP53 and acute myeloid leukemia.